2
李丽娟﹟,黎斌斌,王一民,王春雷,孙凌霄,刘颖梅,鲁炳怀,曹彬*.成人副流感病毒下呼吸道感染患者临床特征和预后分析[J].中华医学杂志,2020,100(27):2109-2115.
4
李丽娟﹟,刘思危,孙凌霄,王一民,刘颖梅,王金祥,任亚莉,刘波,潘建亮,刘菲菲,宋丽斯,王传,曹彬*.成人鼻病毒肺炎临床特征和混合感染病原学特点分析[J].中国呼吸与危重监护杂志,2020,19(05):451-456.
6
Carlos WG, Cruz CSD, Cao B, Gross JE, Pasnick S, Jamil S. COVID-19: How Do We Stay Safe? Am J Respir Crit Care Med. 2020 Sep 1;202(5):P15-P16. doi: 10.1164/rccm.2025P15.
7
Han X﹟*, Liu X, Chen L, Wang Y, Li H, Zhou F, Xing X, Zhang C, Suo L, Wang J, Yu G, Wang G, Yao X, Yu H, Wang L, Liu M, Xue C, Liu B, Zhu X, Li Y, Xiao Y, Cui X, Li L, Cao B; CAP-China network. Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients. BMC Infect Dis. 2020 Sep 12;20(1):668. doi: 10.1186/s12879-020-05362-3.
8
Shang L﹟, Gu X﹟, Du S, Wang Y, Cao B*, Wang C*; CAP-China Network. The efficacy and safety of therapeutic lung lavage for exogenous lipoid pneumonia: a systematic review. Clin Respir J. 2020 Sep 17. doi: 10.1111/crj.13273. Epub ahead of print.
9
Wang Y﹟, Gu X, Xu J, Cao B*, Wang C. Remdesivir and COVID-19 - Authors' reply. Lancet. 2020 Oct 3;396(10256):954. doi: 10.1016/S0140-6736(20)32015-8.
10
Cao B﹟*, Hayden FG. Antiviral monotherapy for hospitalised patients with COVID-19 is not enough. Lancet. 2020 Oct 5;396(10259):1310–1. doi: 10.1016/S0140-6736(20)32078-X. Epub ahead of print.
11
Xu J﹟, Teng Y﹟, Shang L﹟, Gu X, Fan G, Chen Y, Tian R, Zhang S, Cao B*. The Effect of Prior ACEI/ARB Treatment on COVID-19 Susceptibility and Outcome: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2020 Oct 20:ciaa1592. doi: 10.1093/cid/ciaa1592. Epub ahead of print.
12
Sun Y﹟, Li H﹟, Pei Z, Wang S, Feng J, Xu L, Gao P, Cao B,* Zhan S*. Incidence of community-acquired pneumonia in urban China: A national population-based study. Vaccine. 2020 Dec 14;38(52):8362-8370. doi: 10.1016/j.vaccine.2020.11.004. Epub 2020 Nov 13.
13
Zhang Y﹟, Li Y, Zeng J, Chang Y, Han S, Zhao J, Fan Y, Xiong Z, Zou X, Wang C, Li B, Li H, Han J, Liu X, Xia Y, Lu B*, Cao B*. Risk Factors for Mortality of Inpatients with Pseudomonas aeruginosa Bacteremia in China: Impact of Resistance Profile in the Mortality. Infect Drug Resist. 2020 Nov 12;13:4115-4123. doi: 10.2147/IDR.S268744.
14
Zhang Y﹟, Zhao J﹟, Zou X, Fan Y, Xiong Z, Li B, Wang C, Li H, Han J, Liu X, Xia Y, Lu B*, Cao B*; CAP-China network. Severity of influenza virus and respiratory syncytial virus coinfections in hospitalized adult patients. J Clin Virol. 2020 Dec;133:104685. doi: 10.1016/j.jcv.2020.104685.
15
Wang Y﹟, Zhong W﹟, Salam A﹟, Tarning J﹟, Zhan Q﹟, Huang JA﹟, Weng H, Bai C, Ren Y, Yamada K, Wang D, Guo Q, Fang Q, Tsutomu S, Zou X, Li H, Gillesen A, Castle L, Chen C, Li H, Zhen J, Lu B, Duan J, Guo L, Jiang J, Cao R, Fan G, Li J, Hayden FG, Wang C, Horby P, Cao B*. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine. 2020 Nov 21;62:103125. doi: 10.1016/j.ebiom.2020.103125.
16
Shu H﹟, Li L, Wang Y, Guo Y, Wang C, Yang C, Gu L*, Cao B*. Prediction of the Risk of Hospital Deaths in Patients with Hospital-Acquired Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii Infection: A Multi-Center Study. Infect Drug Resist. 2020 Nov 19;13:4147-4154. doi: 10.2147/IDR.S265195.
